OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
OS Therapies Enters into Warrant Inducement Agreements [Yahoo! Finance]
OS Therapies provides first half 2026 corporate outlook [Seeking Alpha]
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)
OS Therapies Provides First Half 2026 Corporate Outlook [Yahoo! Finance]